Category Archives: MS Treatment

"I constantly ask them about the side- effects and that is what I am most unhappy about." Asked for her view on the legal battle, she told BBC Radio 5 Live's Victoria Derbyshire: ''I stand by that. I'm upset that they moved forward in the way they have. ''I'm having to face the side-effects from the radiation and the chemotherapy, which is devastating.'' Ms Roberts, a New Zealander living in Brighton, East Sussex, said ''weak and fragile'' Neon had lost his hair and suffered weight loss, poor short-term memory and poor co-ordination. But, despite the side-effects, Ms Roberts said she has been told the success rate from having the treatment has been put at between 67 per cent and 82 per cent. She said: ''I have never doubted that he was not going to be alive at the end of this, with or without treatment. ''I just felt that he would be much better off without the treatment and providing the body with what it needs to heal, not bombarding it with radiation, which is what we are taught to avoid. ''I don't understand why we are using it in hospitals. I find it barbaric and plain torture. Needlessly, children … Continue reading →

Leading Research Center for Multiple Sclerosis Takes Name of Benefactors NEW YORK, Feb. 26, 2013 /PRNewswire-USNewswire/ -- The Board of Directors of the Multiple Sclerosis Research Center of New York (MSRCNY) today announced the re-naming of the institution as the Tisch MS Research Center of New York. Representing a new model of healthcare, the research center, coupled with its clinical affiliate, the International Multiple Sclerosis Management Practice (IMSMP), is the largest MS facility in the world with over 80,000 square feet at its Manhattan location and serves patients from over 45 countries and five continents. The name change, which is effective immediately, is a reflection of Bonnie and Dan Tisch's long standing support for the research center and an indication of their continued philanthropy to support the Center's mission of unraveling the mysteries of MS at both the cellular and molecular level and ultimately finding a cure. "We are truly honored and grateful for the tremendous generosity of the Tischs and this recognition of the outstanding research being conducted at our Center," stated Dr. Saud A. Sadiq, Director and Senior Research Scientist. "We are confident the Tisch MS Research Center of New York will continue to set the exemplary standard … Continue reading →

A mother has said she stands by her legal bid to try to stop her seven-year-old son receiving radiotherapy for a brain tumour, describing the treatment as "barbaric and plain torture". Neon Roberts's mother has said she stands by her legal bid to try to stop her son receiving radiotherapy (Devon and Cornwall Police/PA) A High Court judge ruled late last year that Sally Roberts' son Neon should undergo radiotherapy for the cancerous tumour against her wishes. Although the youngster has a survival rate of up to 82% now, Ms Roberts, 37, said she was upset by the decision to press ahead with the gruelling treatment. Asked for her view on the legal battle, she told BBC Radio 5 Live's Victoria Derbyshire: "I stand by that. I'm upset that they moved forward in the way they have. I'm having to face the side-effects from the radiation and the chemotherapy, which is devastating." Ms Roberts, a New Zealander living in Brighton, East Sussex, said "weak and fragile" Neon had lost his hair and suffered weight loss, poor short-term memory and poor co-ordination. But, despite the side-effects, Ms Roberts said she has been told the success rate from having the treatment has … Continue reading →

MS Gets on My Nerves Aims to Help Raise Awareness About the Top Disabling Disease Among Young Adults in the U.S. Gloucester, Va. (PRWEB) February 25, 2013 Multiple sclerosis (MS) is an unpredictable, often disabling, disease that attacks the central nervous system, according to the U.S. National Multiple Sclerosis Society. More than 400,000 Americans live with MS. We all need to have the strength to find a cure, said Catesby Jones, Peace Frogs founder and president. Thats why Peace Frogs is pleased to release its newest frog design, MS Gets on My Nerves. MS is the number one disabling disease among young adults in the United States, according to the society. The making of the Peace Frogs MS shirt alone illustrated that startling statistic, Jones said. The slogan came from a friend and fan of Peace Frogs who has MS, Jones said. The shirts were printed by a woman living with MS. And every person on the team knows someone with MS. According to the National MS Societys Hampton Roads chapter, located and serving people near the Peace Frogs headquarters in Virginia, MS symptoms range from numbness and tingling to blindness and paralysis. The advancement, severity and specific symptoms of … Continue reading →

By Mike Dawes PUBLISHED: 07:56 EST, 24 February 2013 | UPDATED: 07:56 EST, 24 February 2013 A career-high 206 not out from Mahendra Singh Dhoni put India firmly in control of the first Test against Australia at the close of play on day three in Chennai. Dhoni smashed 22 fours and five sixes with his knock taking just 243 balls as India finished 515 for eight, 135 ahead of Australia's first-innings effort of 380 all out. Virat Kohli made 107 while Sachin Tendulkar could only add 10 to his overnight score of 71 on a day when Australia toiled in the field. Star of the show: Dhoni hit a quick-fire double hundred to take the game away from Australia Australia made the ideal start when their only frontline spinner, Nathan Lyon, bowled Tendulkar through the gate. His dismissal after a 10-over period of low scoring and disciplined bowling brought in Dhoni, whose arrival prompted an increase in the run rate as he and Kohli took to the visiting bowling attack. Kohli launched a Lyon delivery into the stands in the 68th over before Dhoni found the ropes twice off the same bowler in the 72nd. Moises Henriques was next to … Continue reading →

Chennai: Former India batsman VVS Laxman on Saturday criticized India captain MS Dhoni for keeping aloof from struggling players when they need him most. Laxman, who is part of the Star Cricket commentary team for the first Test against Australia here, gave the example of Harbhajan Singh who he thinks needs plenty of encouragement considering that the offspinner, playing his 100th Test, is going through a lean patch. Laxman was baffled at Dhoni for not bringing Harbhajan into the attack in the first hour of play on day two on Saturday. "Dhoni is sending out the wrong message by keeping Harbhajan on the sidelines. He is making him [Harbhajan] feel unwanted in the team," he said on-air. "A guy who is playing his 100th Test doesn't deserve that sort of treatment." Harbhajan was finally brought into the attack after a gap of 51 overs despite other India bowlers failing to break the dogged stand between overnight batsmen Michael Clarke and Peter Siddle. That miffed Laxman, who said this wasn't the first time that Harbhajan had been looked through by his captain. Getty Images "When Harbhajan returned after a long time for the Mumbai Test against England late last year, he … Continue reading →

* Elan (Other OTC: ELNCF - news) to buy back $1 bln of shares after Tysabri sale * Deal is "unique opportunity" to reward shareholders * Firm still working on acquisitions with rest of proceeds * Shares climb over 4 percent By Stephen Mangan DUBLIN, Feb 22 (Reuters) - Irish drugmaker Elan will return $1 billion to shareholders, giving them an immediate boost from the sale of its stake in multiple sclerosis (MS) treatment Tysabri to partner Biogen Idec (NasdaqGS: BIIB - news) . Elan shares climbed over 4 percent following the announcement on Friday, which also reiterated the company's intention to make acquisitions with the rest of the $3.25 billion raised from the deal. Tysabri was by far Elan's most important product, responsible for almost all its revenue and its sale creates uncertainty over the future shape of the company. "Close to 40 percent of Elan's current market cap could be invested in as yet unknown assets ... we are unlikely to gain the visibility needed to become constructive on the shares until transactions are concluded," said Deutsche Bank (Xetra: 514000 - news) analyst Richard Parkes. Elan is already pursuing potential deals for the next 12-18 months, Chief Executive … Continue reading →

DUBLIN (Reuters) - Irish drugmaker Elan (Other OTC: ELNCF - news) will return $1 billion (654 million pounds) to shareholders and seek acquisitions with the proceeds of selling its stake in blockbuster multiple sclerosis (MS) treatment Tysabri to partner Biogen Idec (NasdaqGS: BIIB - news) . The sale of Tysabri, which was by far Elan's most important product and responsible for almost all its revenue, leaves the company's future shape unclear, but the deal now offers it flexibility to buy new assets. The company said on Friday it would use almost a third of the $3.25 billion from the deal to buy back shares. "By unlocking a portion of the Tysabri asset value ... we have a unique opportunity to reward shareholders, diversify our business and create a highly distinctive business platform upon which to advance to the benefit of shareholders and patients around the world," Elan Chief Executive CEO Kelly Martin said. Elan is already pursuing potential deals for the next 12-18 months, Martin told Reuters in an interview earlier this month, which he said may not necessarily be restricted to the company's past. The Irish drugmaker has co-marketed Tysabri with the larger U.S. company for 12 years and … Continue reading →

The MS Center of Atlanta, along with the NMSS (National Multiple Sclerosis Society), are dedicated to remove all barriers to patient care. The Center is proud to team up with GPT (Georgia Partnership of Telehealth) and Dr. Brian Griner to set up the first dedicated telehealth center for MS in Valdosta, Georgia. (PRWEB) February 22, 2013 The MS Center of Atlanta, along with the NMSS (National Multiple Sclerosis Society), are dedicated to remove all barriers to patient care. The Center is proud to team up with GPT (Georgia Partnership of Telehealth) and Dr. Brian Griner to set up the first dedicated telehealth center for MS in Valdosta, Georgia. Dr. Griner is a Primary Care Physician and Dr. Jeffrey English along with the Centers other staff neurologist are on the MS Center side of this partnership. Patients will be able to see their MS specialist immediately from a primary care facility without traveling 4.5 hours (each way). The Center is to have sites across Georgia and hope the future will allow such care directly from every primary care physician's office. Separately Dr. English is developing similar relationships for concussion management through SCI-Atlanta (Sports Concussion Institute at Atlanta). Athletes with suspected concussion … Continue reading →

DUBLIN (Reuters) - Irish drugmaker Elan will return $1 billion to shareholders, giving them an immediate boost from the sale of its stake in multiple sclerosis (MS) treatment Tysabri to partner Biogen Idec. Elan shares climbed over 4 percent following the announcement on Friday, which also reiterated the company's intention to make acquisitions with the rest of the $3.25 billion raised from the deal. Tysabri was by far Elan's most important product, responsible for almost all its revenue and its sale creates uncertainty over the future shape of the company. "Close to 40 percent of Elan's current market cap could be invested in as yet unknown assets ... we are unlikely to gain the visibility needed to become constructive on the shares until transactions are concluded," said Deutsche Bank analyst Richard Parkes. Elan is already pursuing potential deals for the next 12-18 months, Chief Executive Kelly Martin told Reuters in an interview this month, which he said may not necessarily be restricted to the firm's past areas of activity. "By unlocking a portion of the Tysabri asset value ... we have a unique opportunity to reward shareholders, diversify our business and create a highly distinctive business platform upon which to … Continue reading →